Navigation Links
Biotrial, a Successful Leading CRO, Continues to Expand its Activities, Creating a Unique Neuroscience Pool of Talent and Capabilities: Biotrial Neuroscience
Date:4/1/2013

(PRWEB) April 01, 2013

In order to meet the biopharmaceutical market’s growing need for niche services and cutting-edge technology, Biotrial announced today that it has reinforced its existing CNS group through the acquisition of equipment and key talent from the leading CNS focused CRO, Forenap.

For over 20 years, Biotrial has been very active in CNS drug evaluation, conducting trials to fully assess the psychoactive properties of compounds. The aim of the new Biotrial Neuroscience division is to give clients access to a unique pool of scientific expertise, state-of-the-art equipment, and a collaborative environment with other Biotrial groups of excellence: the Non-Clinical Department dedicated to in vivo evaluation, model development and translational medicine, the Clinical Department involved in Early Phase Healthy Volunteer and Patient Studies, Biotrial Bioanalytical Services (BBS) that offers capabilities for bioanalysis, custom assay development and validation as well as biomarker quantification, and the Biotrial Core Lab for centralized PD assessments (EEG, ECG, etc.) in mono- or multicentric trials.

Jean-Marc Gandon, PharmD, Biotrial President and CEO, commented on the enhanced expertise: “Targeted medicine is at the heart of innovation right now and there is an increasing trend to perform clinical trials with a pharmacological and therapeutic approach very early on. CNS has been a key area for many years at Biotrial, so when we heard that Forenap was unfortunately closing we wanted to integrate some of Forenap’s highly qualified and motivated individuals into our CNS team, as well as their research center’s state-of-the-art equipment. This stage is now completed and we have fully established our extensive testing capabilities to help our clients with their projects in neuropsychiatry and neurocognitive diseases, as well as pain relief therapies.”

Philippe Danjou, Biotrial’s R&D Director, stated: “I am extremely proud to have had the opportunity to join the dynamic team at Biotrial in an R&D role. Today’s environment of developing differentiated drugs that deliver proven patient benefits is more challenging than ever, especially in the CNS domain, so having strong capabilities and expertise in-house is necessary for a CRO to fully meet their clients’ needs. Biotrial Neuroscience has capitalized on broad experience and a solid track record in conducting CNS-focused clinical trials, and with the integration of Forenap’s experienced personnel and equipment, Biotrial Neuroscience now provides more extensive services in the field of Electrophysiology (EEG, ERPs), Sleep studies, Neuroimaging and Pain models.”

About Biotrial
Founded in 1989, Biotrial is a leading CRO specialized in Early Development with a wide range of services from Non-Clinical Pharmacology, Phase I studies, Phase II-IV Trial Management, Bioanalysis, Oncology, Data Management, Biostatistics, ECG & Imaging Core Lab (QT/QTc Trials, Psychometric Testing, Imaging, EEG/PSG Assessment), Regulatory Affairs to Medical Writing.

Based in France, Belgium, the United Kingdom, Canada and the United States, Biotrial performs hundreds of studies a year and offers tailor-made solutions to Biotech and Pharmaceutical companies.

For further information please contact Anne Peron on [+33] 029-959-9191 or visit http://www.biotrial.com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10580700.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division
2. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
3. Another Successful Year at Divine Skin
4. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
5. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
6. Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
7. RiverVest Venture Partners Sells Four Successful Life Science Companies for More than $1 Billion
8. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
9. Successful human tests for first wirelessly controlled drug-delivery chip
10. First successful human results achieved: Implantable wireless microchip drug delivery device
11. Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its ... new website makes it easy to navigate through the site whether you’re in ... detailed product information, educational industry content and visit the company’s social media accounts, ...
(Date:8/11/2017)... ... , ... A staple in the community for more than 60 years, Bill ... including a new digital marketing strategy and updated logo. , As part of the ... with the South Texas Blood & Tissue Center for the month of August. ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... , ... August 10, 2017 , ... ... agreement establishing Kinokuniya Company Ltd. as its exclusive sales representative for SPIE Journals ... representative for the SPIE Digital Library in Japan. , “We look forward to ...
Breaking Biology Technology:
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):